Related Experiment Video
Updated: Jan 17, 2026

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
Published on: April 23, 2019
Access, Value and Reform: An Analysis of Canada's Pharmaceutical Policy Framework
1Former Executive Director, Patented Medicine Prices Review Board, Former Chief Executive Officer, Pan-Canadian Pharmaceutical Alliance, Ottawa, ON.
Canada effectively attracts essential innovative drugs, contrary to industry claims. National pharmacare could address system inefficiencies and improve drug access for patients.
Area of Science:
- Health Policy
- Pharmaceutical Economics
- Drug Access
Background:
- Pharmaceutical industry claims Canada lags in innovative drug access due to policy issues.
- Previous article argued Canada successfully attracts key new drugs, with minimal impact from price or IP changes.
- Industry concerns exist regarding system inefficiencies due to federal-provincial fragmentation.
Purpose of the Study:
- To respond to an article challenging pharmaceutical industry claims on drug access in Canada.
- To evaluate the impact of potential policy changes on innovative drug launches.
- To propose solutions for improving drug access and system efficiencies.
Main Methods:
- Rejoinder analysis of existing arguments and industry claims.
- Assessment of the relationship between drug pricing, intellectual property, and market access.
- Examination of healthcare system structure, including federal-provincial dynamics.
Main Results:
- Canada successfully attracts most critical innovative drugs.
- Higher prices or stronger intellectual property protection would negligibly impact drug launch timing and scope.
- Federal-provincial fragmentation causes system inefficiencies, but national pharmacare offers a potential resolution.
Conclusions:
- Canada's drug access is robust for key innovations, challenging industry assertions.
- National pharmacare could reconcile pharmaceutical industry and payer concerns regarding system inefficiencies.
- Thoughtful reform, research into unmet needs, and a focus on patient-relevant outcomes are crucial for improving drug access.
More Related Videos
07:48Tracking Drug-induced Changes in Receptor Post-internalization Trafficking by Colocalizational Analysis
Published on: July 3, 2015
08:31Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
Published on: December 1, 2020
Related Concept Videos
Drug Control Governance: Regulatory Bodies and Their Impact
Drug Products: Biologics, Biosimilars and Interchangeables
Drug Regulation
Biopharmaceutical Factors Influencing Drug Product Design: Overview
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Biopharmaceutics and Pharmacokinetics: Overview